Topics

FDA Grants Breakthrough Therapy Designation to AstraZeneca’s Calquence for Treatment of Chronic Lymphocytic Leukemia

13:43 EDT 15 Aug 2019 | Speciality Pharma Journal

WILMINGTON, Del.–(BUSINESS WIRE)–AstraZeneca today announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) for CALQUENCE® (acalabrutinib) as a monotherapy treatment for adult patients with chronic lymphocytic leukemia (CLL), one of the most common types of leukemia in adults. José Baselga, Executive Vice President, Oncology R&D, said: “This is an important …

Original Article: FDA Grants Breakthrough Therapy Designation to AstraZeneca’s Calquence for Treatment of Chronic Lymphocytic Leukemia

NEXT ARTICLE

More From BioPortfolio on "FDA Grants Breakthrough Therapy Designation to AstraZeneca’s Calquence for Treatment of Chronic Lymphocytic Leukemia"

Quick Search

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...